Xeris Biopharma Holdings (XERS) Assets Average (2021 - 2026)

Xeris Biopharma Holdings has reported Assets Average for 6 years, with the latest figure at $387.8 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 21.46% year-over-year to $387.8 million; the trailing twelve-month figure through Mar 2026 stood at $387.8 million (up 21.46% YoY), and the FY2025 full-year result was $353.3 million, up 9.44% from the prior year.
• Assets Average for Q1 2026 stood at $387.8 million, up from $376.9 million in the prior quarter.
• The five-year high for Assets Average was $387.8 million in Q1 2026, with the low at $310.8 million in Q3 2022.
• Historically, Assets Average has averaged $333.5 million across 5 years, with a median of $326.4 million in 2024.
• Annual changes were most pronounced in 2022 — Assets Average surged 48.65% — and 2025, when it decreased 3.14%.
• Xeris Biopharma Holdings' Assets Average stood at $323.8 million in 2022, then rose by 0.44% to $325.2 million in 2023, then fell by 0.96% to $322.1 million in 2024, then climbed by 17.01% to $376.9 million in 2025, then gained by 2.9% to $387.8 million in 2026.
• The last three Assets Average figures came in at $387.8 million (Q1 2026), $376.9 million (Q4 2025), and $352.4 million (Q3 2025), per Business Quant data.